These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 1526540)

  • 1. [Long-term bezafibrate treatment in a lipid clinic].
    Yeshurun D; Abukarshin R; Ellias N; Naschitz JE
    Harefuah; 1992 May; 122(10):632-4, 687. PubMed ID: 1526540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia].
    Arntz HR; Klemens UH; Vollmar LJ; Lang PD
    Med Klin; 1978 Dec; 73(49):1731-7. PubMed ID: 723760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination.
    Yeshurun D; Abukarshin R; Elias N; Lanir A; Naschitz JE
    Clin Ther; 1993; 15(2):355-63. PubMed ID: 8519043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
    Manfredi R; Chiodo F
    J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
    Grützmacher P; Scheuermann E; Lang W
    Proc Eur Dial Transplant Assoc; 1981; 18():169-75. PubMed ID: 7036147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Acipimox (Olbetam) as a secondary hypolipemic agent in combined hypertriglyceridemia and hyperlipidemia].
    Yeshurun D; Hamood H; Morad N; Naschitz J
    Harefuah; 2000 Apr; 138(8):650-3, 710. PubMed ID: 10883206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate].
    Schiffl H; Weidmann P; Fragiacomo C; Noseda G; Bachmann C
    Schweiz Med Wochenschr; 1985 Jun; 115(26):907-11. PubMed ID: 3927481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homocysteine elevation with fibrates: is it a class effect?
    Harats D; Yodfat O; Doolman R; Gavendo S; Marko D; Shaish A; Sela BA
    Isr Med Assoc J; 2001 Apr; 3(4):243-6. PubMed ID: 11344833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A comparison of bezafibrate and lovastatin treatment at the usual doses in post-heart transplant hyperlipemia].
    Zambrana García JL; López Miranda J; Anguita Sánchez M; Blanco Cerrada J; Vallés Belsúe F; Casares Mediavilla J; Muñoz Carvajal I; Jiménez Perepérez JA; Pérez Jiménez F
    Rev Esp Cardiol; 1996 Dec; 49(12):892-8. PubMed ID: 9026840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of bezafibrate & nicotinic acid on triton induced hyperlipidemias in CFY rats.
    Krishnamurthy A; Thapar GS
    Indian J Med Res; 1991 Oct; 94():395-8. PubMed ID: 1794899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lovastatin versus bezafibrate for hyperlipemia treatment after heart transplantation.
    Hidalgo L; Zambrana JL; Blanco-Molina A; López-Granados A; Concha M; Casares J; Jiménez-Pérez J; López-Miranda J; Pérez-Jiménez F
    J Heart Lung Transplant; 1995; 14(3):461-7. PubMed ID: 7654731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of lovastatin and bezafibrate on cyclosporine-induced hyperlipidemia in rabbits.
    Hidalgo L; López-Miranda J; Espino A; Alcala J; Blanco J; Prada JL; Rodríguez M; Jiménez-Perepérez JA; Jansen S; Pérez-Jiménez F
    Transplant Proc; 1995 Apr; 27(2):1857-61. PubMed ID: 7725532
    [No Abstract]   [Full Text] [Related]  

  • 13. [Statistical analysis of variations in total cholesterol, HDL, HDL2, HDL3, LDL-cholesterol, VLDL-triglycerides, apo-A and apo-B lipoproteins in dyslipidemias during antilipemic therapy].
    Melloni GF; Scarazatti E; Garanzelli P; Melloni R
    Boll Soc Ital Biol Sper; 1985 Jan; 61(1):7-14. PubMed ID: 3884023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in the concentration and composition of lipids and lipoproteins in primary hyperlipoproteinemia during treatment with bezafibrate.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(8):1185-90. PubMed ID: 6685498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment of severe familial hypercholesterolemia in children: effect of sitosterol and bezafibrate.
    Becker M; Staab D; Von Bergman K
    Pediatrics; 1992 Jan; 89(1):138-42. PubMed ID: 1727999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of the efficacy of pantethine, acipimox, and bezafibrate on plasma lipids and index of cardiovascular risk in diabetics with dyslipidemia].
    Tonutti L; Taboga C; Noacco C
    Minerva Med; 1991 Oct; 82(10):657-63. PubMed ID: 1745376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Artery; 1980; 8(2):113-9. PubMed ID: 7458676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with bezafibrate.
    Schubotz R; Schneider J; Hausmann L; Mühlfellner G; Mühlfellner O; Kaffarnik H
    Artery; 1980; 8(6):553-9. PubMed ID: 7259534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
    Saku K; Sasaki J; Arakawa K
    Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: a pilot study.
    Mathur S; Barradas MA; Mikhailidis DP; Dandona P
    Diabetes Res; 1990 Jul; 14(3):133-8. PubMed ID: 2132185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.